These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811 [TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19. Boras B; Jones RM; Anson BJ; Arenson D; Aschenbrenner L; Bakowski MA; Beutler N; Binder J; Chen E; Eng H; Hammond H; Hammond J; Haupt RE; Hoffman R; Kadar EP; Kania R; Kimoto E; Kirkpatrick MG; Lanyon L; Lendy EK; Lillis JR; Logue J; Luthra SA; Ma C; Mason SW; McGrath ME; Noell S; Obach RS; O' Brien MN; O'Connor R; Ogilvie K; Owen D; Pettersson M; Reese MR; Rogers TF; Rosales R; Rossulek MI; Sathish JG; Shirai N; Steppan C; Ticehurst M; Updyke LW; Weston S; Zhu Y; White KM; García-Sastre A; Wang J; Chatterjee AK; Mesecar AD; Frieman MB; Anderson AS; Allerton C Nat Commun; 2021 Oct; 12(1):6055. PubMed ID: 34663813 [TBL] [Abstract][Full Text] [Related]
7. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Vangeel L; Chiu W; De Jonghe S; Maes P; Slechten B; Raymenants J; André E; Leyssen P; Neyts J; Jochmans D Antiviral Res; 2022 Feb; 198():105252. PubMed ID: 35085683 [TBL] [Abstract][Full Text] [Related]
8. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332. Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231 [TBL] [Abstract][Full Text] [Related]
9. Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro. Zhang L; Liu J; Cao R; Xu M; Wu Y; Shang W; Wang X; Zhang H; Jiang X; Sun Y; Hu H; Li Y; Zou G; Zhang M; Zhao L; Li W; Guo X; Zhuang X; Yang XL; Shi ZL; Deng F; Hu Z; Xiao G; Wang M; Zhong W Virol Sin; 2020 Dec; 35(6):776-784. PubMed ID: 32910347 [TBL] [Abstract][Full Text] [Related]
10. Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2. Drayman N; DeMarco JK; Jones KA; Azizi SA; Froggatt HM; Tan K; Maltseva NI; Chen S; Nicolaescu V; Dvorkin S; Furlong K; Kathayat RS; Firpo MR; Mastrodomenico V; Bruce EA; Schmidt MM; Jedrzejczak R; Muñoz-Alía MÁ; Schuster B; Nair V; Han KY; O'Brien A; Tomatsidou A; Meyer B; Vignuzzi M; Missiakas D; Botten JW; Brooke CB; Lee H; Baker SC; Mounce BC; Heaton NS; Severson WE; Palmer KE; Dickinson BC; Joachimiak A; Randall G; Tay S Science; 2021 Aug; 373(6557):931-936. PubMed ID: 34285133 [TBL] [Abstract][Full Text] [Related]
11. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity. Morita T; Miyakawa K; Jeremiah SS; Yamaoka Y; Sada M; Kuniyoshi T; Yang J; Kimura H; Ryo A Viruses; 2021 Aug; 13(8):. PubMed ID: 34452533 [TBL] [Abstract][Full Text] [Related]
12. Mitigation of the replication of SARS-CoV-2 by nitric oxide in vitro. Akaberi D; Krambrich J; Ling J; Luni C; Hedenstierna G; Järhult JD; Lennerstrand J; Lundkvist Å Redox Biol; 2020 Oct; 37():101734. PubMed ID: 33007504 [TBL] [Abstract][Full Text] [Related]
13. Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508 [TBL] [Abstract][Full Text] [Related]
15. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Chiou WC; Chen JC; Chen YT; Yang JM; Hwang LH; Lyu YS; Yang HY; Huang C Biochem Biophys Res Commun; 2022 Feb; 591():130-136. PubMed ID: 33454058 [TBL] [Abstract][Full Text] [Related]
16. Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Yinda CK; Port JR; Bushmaker T; Fischer RJ; Schulz JE; Holbrook MG; Shaia C; de Wit E; van Doremalen N; Munster VJ Emerg Microbes Infect; 2021 Dec; 10(1):1284-1292. PubMed ID: 34120579 [TBL] [Abstract][Full Text] [Related]
17. A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*. Yang KS; Ma XR; Ma Y; Alugubelli YR; Scott DA; Vatansever EC; Drelich AK; Sankaran B; Geng ZZ; Blankenship LR; Ward HE; Sheng YJ; Hsu JC; Kratch KC; Zhao B; Hayatshahi HS; Liu J; Li P; Fierke CA; Tseng CK; Xu S; Liu WR ChemMedChem; 2021 Mar; 16(6):942-948. PubMed ID: 33283984 [TBL] [Abstract][Full Text] [Related]
18. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 Good SS; Westover J; Jung KH; Zhou XJ; Moussa A; La Colla P; Collu G; Canard B; Sommadossi JP Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558299 [TBL] [Abstract][Full Text] [Related]